Physician profile
Catherine Permin
NPI 1265579700
$4,344.24
in general payments reported to CMS, 2019-2025
25 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $758 · 2023: $1,405 · 2024: $1,387 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,276.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,186.66 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $851.06 | 2021-2025 | Caplyta |
| Genzyme Corporation | $265.17 | 2022-2024 | |
| Gilead Sciences, INC. | $239.40 | 2023-2024 | Epclusa |
| Evoke Pharma, INC. | $226.96 | 2023-2024 | Gimoti |
| Otsuka America Pharmaceutical, INC. | $157.41 | 2023-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $149.02 | 2023-2024 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $147.25 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $138.75 | 2021-2024 | Invega Sustenna |
| Astellas Pharma US INC | $120.82 | 2024 | Cresemba |
| Paratek Pharmaceuticals, INC. | $100.49 | 2022 | |
| Idorsia Pharmaceuticals US INC | $100.46 | 2023 | Quviviq |
| Neurelis, INC. | $93.00 | 2025 | Valtoco |
| Acadia Pharmaceuticals INC | $78.30 | 2024 | Nuplazid |
| Alkermes, INC. | $62.40 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $62.37 | 2023-2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $55.88 | 2022 | |
| Noven Therapeutics, LLC | $55.66 | 2023-2024 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $55.10 | 2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $47.22 | 2023 | Uzedy, Austedo |
| E.R. Squibb & Sons, L.L.C. | $45.19 | 2024 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $35.74 | 2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $29.50 | 2024 | Qelbree |
| Bausch Health US, LLC | $24.45 | 2023 | Wellbutrin, Aplenzin |
| Lundbeck LLC | $15.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Permin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.